Home / News & Updates

News & Updates

Case breakthroughs, oncology advances, and resources from Beijing Arion Cancer Hospital — UPMC-affiliated tertiary cancer center.

dMMR endometrial cancer with brain metastases — ADC plus immunotherapy rescue — Case Breakthrough Vol. 18
Case Breakthrough July 9, 2026

Widespread Metastases, Repeated Brain Progression — ADC Combined with Immunotherapy Reverses Late-Stage dMMR Endometrial Cancer Crisis

51-year-old female with dedifferentiated dMMR endometrial carcinoma (IIIB–IVB). Post-op widespread mets + brain mets with tentorial herniation. First-line chemo-immuno + WBRT achieved PR. Upon intracranial progression, sacituzumab govitecan + pembrolizumab with individualized dosing (5→4 mg/kg) and single-dose bevacizumab for edema control delivered 13+ months of stable disease — a >4× extension over GPA-predicted survival. Commentary by Prof. Wu Ming (PUMCH) & Prof. Sun Min (UPMC).

Read More →
89-year-old woman with three primary cancers receiving precision radiotherapy — Case Breakthrough Vol. 17
Case Breakthrough July 9, 2026

Three Cancers at Age 89: When Targeted & Immunotherapy Both Fail — Precision RT Restores Ambulatory Function and Delivers High-Quality Survival

An 89-year-old female with colon cancer, bladder cancer, and recurrent malignant peripheral nerve sheath tumor (15 cm) experienced severe toxicity from both anlotinib (hematuria, hydronephrosis) and tislelizumab (fever, AKI). Dual-site SBRT achieved significant tumor shrinkage, restored independent walking, with only Grade 1 toxicity. Expert commentary by Prof. Cai Yong (Peking University Cancer Hospital).

Read More →
Prof. Xiao Yu from Peking University Third Hospital, Dr. Jiang Bin from Arion, and Prof. Sun Min from UPMC on two-stage hepatectomy for diffuse colorectal liver metastases — Case Breakthrough Vol. 16
Case Breakthrough July 9, 2026

Breaking Through Palliative Limits: Two-Stage Hepatectomy with Portal Vein Ligation Transforms Unresectable Colorectal Liver Metastases into a Curative Opportunity

60-year-old man with sigmoid colon cancer (pT4aN1M1) and diffuse whole-liver mets (>10 lesions). FOLFOX+cetuximab achieved CEA 191→3.12 ng/mL but FLR insufficient for one-stage resection. Arion MDT selected TSH-PVL over ALPPS: Stage-I laparoscopic colectomy + left liver mets clearance (9 lesions) + right PVL → HAIC+FOLFOX interval → Stage-II right hemihepatectomy planned. Expert commentary by Profs. Xiao Yu (PKU Third Hospital) & Sun Min (UPMC).

Read More →
Prof. Sun Min from UPMC and Prof. Bai Li from PLA General Hospital on rare intrasinusoidal breast cancer liver metastasis reversed by T-DXd — Case Breakthrough Vol. 15
Case Breakthrough July 9, 2026

Breaking the End-Stage Verdict: CDK4/6i Rapid Resistance Near Death — Rare Sinusoidal Metastasis Identified by MDT, ADC Therapy Reverses Visceral Crisis

46F with HR+/HER2-low metastatic breast cancer developed rapid progression on ribociclib (PFS only 13 months), presenting as visceral crisis: acute liver failure (AST 320 U/L), severe hypoxemia (SpO&sub2; 81%), and portal vein flow reversal. Arion's MDT diagnosed rare diffuse intrasinusoidal hepatic metastasis causing hepatopulmonary syndrome through pathophysiological reasoning — confirmed by liver biopsy. T-DXd rescue normalized portal flow in 2 weeks, achieved PR after 3 cycles. Expert commentary by Profs. Sun Min (UPMC) & Bai Li (PLA General Hospital).

Read More →
Prof. Yu Chunhua from PUMCH and Prof. Zhou Wan from Beijing Arion Cancer Hospital on high-risk anesthesia enabling thyroid cancer surgery in a patient with complex congenital heart disease — Case Breakthrough Vol. 14
Case Breakthrough July 9, 2026

Defying Surgical Contraindication: High-Stakes Anesthesia Management Enables Curative Thyroid Cancer Resection in a Patient with Complex Congenital Heart Disease

A 46-year-old woman with papillary thyroid cancer was rejected by multiple hospitals due to complex congenital heart disease (single atrium, single ventricle, transposition of great arteries, severe pulmonary stenosis, SpO2 77-81%). Arion's anesthesia-led MDT team delivered precision perioperative management — 6-pillar strategy, slow-sequence induction, protective lung ventilation, continuous vasoactive support — achieving safe total thyroidectomy with neck dissection in 3h03m, extubated in OR, discharged on Day 2. Expert commentary by Prof. Yu Chunhua (PUMCH).

Read More →
Prof. Xue Weicheng from Peking University Cancer Hospital and Prof. Zhang Bo from Beijing Arion Cancer Hospital on Primary Mediastinal Large B-Cell Lymphoma — Case Breakthrough Vol. 13
Case Breakthrough July 9, 2026

Seemingly Dangerous, Yet Highly Curable: A Clinical Guide to Primary Mediastinal Large B-Cell Lymphoma — The Disease That Straddles Two Worlds

A 45-year-old woman with an anterior mediastinal mass was diagnosed with PMBCL — a unique lymphoma that bridges Hodgkin and non-Hodgkin classifications. Complete IHC profiling (CD20+, CD30+, MUM1+, Bcl-2+, high Ki67) reveals its hybrid biology. With 5-year survival of 80–90%, accurate diagnosis unlocks highly effective immunochemotherapy and emerging immunotherapies. Expert commentary by Prof. Xue Weicheng (Peking University Cancer Hospital).

Read More →
Prof. Zhang Wei from PUMCH and Prof. Wang Wenyan from Arion on refractory DLBCL treated with bispecific antibody after dual CAR-T failure — Case Breakthrough Vol. 12
Case Breakthrough July 9, 2026

When Two CAR-T Therapies Fail: How Sequential Bispecific Antibody Rescues Refractory Diffuse Large B-Cell Lymphoma

A 57-year-old woman with multi-refractory DLBCL failed two CAR-T cell therapies (CD20-targeted, then novel CD19/PD1/CD28 LM101) due to T-cell exhaustion and poor expansion. MDT-guided sequential glofitamab (CD20/CD3 bispecific antibody) achieved disease control with normalized blood counts, resolved lymphadenopathy, and no Grade ≥ 2 toxicity. Expert commentary by Prof. Zhang Wei (PUMCH).

Read More →
Prof. Bai Li, Prof. Yang Xuhui, and Prof. Han Chun on cholangiocarcinoma liver metastasis treated with HAIC combined with immunotherapy — Case Breakthrough Vol. 11
Case Breakthrough July 9, 2026

Rapid Recurrence 4 Months Post-Surgery and No Options Left? HAIC Combined with Immunotherapy Achieves a Breakthrough in Desperate Circumstances

A 58-year-old man with cholangiocarcinoma developed liver metastasis just 4 months after Whipple procedure (T3N0M0). With PD-L1 CPS=65 and KRAS G12R mutation, MDT-guided hepatic arterial infusion chemotherapy (HAIC) with nal-IRI + tislelizumab achieved stable disease and PFS exceeding 1 year — navigating a critical "mixed response" at cycle 5. Expert commentary by Prof. Bai Li (PLA General Hospital).

Read More →
Prof. Wu Ming and Prof. Li Liping on the value of ultrasound-guided biopsy in distinguishing cervical lymphoma from cervical cancer — Case Breakthrough Vol. 10
Case Breakthrough July 8, 2026

Cervical Mass ≠ Cervical Cancer: How Ultrasound-Guided Biopsy Revealed a Rare Lymphoma in a 53-Year-Old Woman

A 53-year-old woman with a 7-cm cervical mass suspected as cancer — but HPV-negative and TCT ASC-US — underwent MDT evaluation with ultrasound re-assessment showing diffuse hypoechoic texture with preserved cervical canal. Transvaginal ultrasound-guided biopsy diagnosed non-Hodgkin DLBCL, NOS, GCB type. She achieved clinical cure with 6 months of rituximab-based therapy. Expert commentary by Prof. Wu Ming (Peking Union Medical College Hospital).

Read More →
Prof. Qiao Zhiyu and Prof. Luo Yong on high-risk ureteral cancer with multiple arterial aneurysms — Case Breakthrough Vol. 9
Case Breakthrough July 8, 2026

Rejected by 5 Hospitals: How MDT Defuses Two Lethal Threats — High-Risk Ureteral Cancer with Thoracic, Abdominal, and Iliac Aneurysms

A 65-year-old woman with high-risk ureteral cancer complicated by severe thoracic aortic aneurysm (ulcerative transmural type at the arch), abdominal/iliac aneurysms, CAD, and PE — turned away by five hospitals — achieves R0 laparoscopic radical resection with only 20mL blood loss through Arion's specialized cardiovascular-oncology MDT. Now on adjuvant disitamab vedotin + toripalimab. Expert commentary by Prof. Qiao Zhiyu (Beijing Anzhen Hospital).

Read More →
Prof. Xiao Yu and Prof. Jiang Bin on MSI-H duodenal mixed carcinoma dual immunotherapy conversion and MDT radical resection — Case Breakthrough Vol. 8
Case Breakthrough July 8, 2026

When Pathology Surprises Everyone: How Dual Immunotherapy Conversion + MDT-Guided Radical Pancreaticoduodenectomy Achieved R0 Resection in MSI-H Duodenal Mixed Carcinoma

A 57-year-old woman with locally advanced MSI-H duodenal adenocarcinoma, complete obstruction, jaundice, and severe malnutrition undergoes neoadjuvant dual immunotherapy (ipilimumab + nivolumab) achieving CEA reduction from 245 to 68 ng/ml, followed by radical pancreaticoduodenectomy (R0) — only to reveal postoperative mixed neuroendocrine-non-neuroendocrine carcinoma. Now on adjuvant EP + immune maintenance. Expert commentary by Prof. Xiao Yu (Peking University Third Hospital).

Read More →
Prof. Cai Yong on MDT-guided IMRT + Traditional Chinese Medicine for 82-year-old gastric cancer patient on dialysis — Case Breakthrough Vol. 7
Case Breakthrough July 8, 2026

When Surgery Is Not an Option: How MDT-Guided IMRT + Traditional Chinese Medicine Achieved Over 1-Year Stable Disease in an 82-Year-Old Gastric Cancer Patient on Dialysis

An 82-year-old man with locally advanced gastric adenocarcinoma, chronic renal failure on dialysis, and post-coronary stent history achieves partial response and over 1-year stable disease through MDT-guided IMRT (45Gy/25 fractions) combined with individualized Traditional Chinese Medicine — without surgery, chemotherapy, or a single Grade 3 adverse event. Expert commentary by Prof. Cai Yong (Peking University Cancer Hospital).

Read More →
Prof. Sun Min and Prof. Pan Yong on AKT1-mutant advanced breast cancer precision therapy with Capivasertib — Case Breakthrough Vol. 6
Case Breakthrough July 7, 2026

From CDK4/6 to ADC to AKT Inhibitor: How Precision Oncology Breaks Through Multi-Line Resistance in HR+/HER2- Advanced Breast Cancer

A 42-year-old woman with HR+/HER2- advanced breast cancer, resistant after CDK4/6 inhibitor, HDAC inhibitor, chemotherapy, and ADC therapy, achieves partial response through AKT inhibitor (Capivasertib) + fulvestrant guided by AKT1 p.E17K mutation — with MDT-managed Grade 3 rash that never stopped treatment. Expert commentary by Prof. Sun Min (UPMC).

Read More →
Prof. Zhang Junting and Prof. Hong Ganlin on adult primary intracranial sarcoma DICER1-mutant case — Case Breakthrough Vol. 5
Case Breakthrough July 7, 2026

When No Guidelines Exist: How MDT Creates a Treatment Path for Extremely Rare Adult Primary Intracranial Sarcoma, DICER1-Mutant

A 23-year-old man with a newly defined WHO entity (2021) — primary intracranial sarcoma, DICER1-mutant (Grade 4), initially misdiagnosed as CNS lymphoma — achieves gross total resection (GTR) followed by ICE chemotherapy and concurrent radiation, with 5 cycles completed and full functional preservation. With expert commentary from Prof. Zhang Junting (Beijing Tiantan Hospital).

Read More →
Prof. Zhang Shucai and Prof. Zhang Min on high tumor burden ES-SCLC quadruplet therapy — Case Breakthrough Vol. 4
Case Breakthrough July 7, 2026

When Every Organ Is Under Attack: Quadruplet Therapy + Staged Radiation Achieves 7+ Month PFS in High Tumor Burden ES-SCLC

A 67-year-old woman with extensive-stage small cell lung cancer and metastases to the brain, spleen, liver, and lymph nodes achieves 7+ month PFS through quadruplet therapy (etoposide + carboplatin + durvalumab + anlotinib), staged precision radiation, and lurbinectedin + durvalumab maintenance. With expert commentary from Prof. Zhang Shucai (Beijing Chest Hospital).

Read More →
Prof. Wu Ming and Prof. Li Ya from Peking Union Medical College Hospital collaborating with Arion on complex gynecologic tumor case — Case Breakthrough Vol. 3
Case Breakthrough July 7, 2026

When Pathology Changes Three Times and Pulmonary Embolism Strikes: How MDT Achieves a Pathologic Complete Response in Dual Primary Gynecologic Cancer

A 68-year-old woman with dual primary cancers—endometrial clear cell carcinoma and undifferentiated ovarian sarcoma—navigates three pathology shifts, a life-threatening pulmonary embolism, and achieves pCR through neoadjuvant immunotherapy and MDT surgery. With expert commentary from Prof. Wu Ming (Peking Union Medical College Hospital).

Read More →

Medical Resources

Useful information for international patients considering cancer treatment in China.

📄

Understanding Cancer Staging

A guide to TNM staging, pathology reports, and what your diagnosis means for treatment options and prognosis.

Coming soon →
📖

Preparing for Your MDT Consultation

What to bring to your first MDT consultation at Arion: medical records, imaging, pathology slides, list of questions, and more.

Remote consultation guide →
✈

Travel Guide for Cancer Patients

Practical tips for international travel during cancer treatment: what to pack, medication management, and staying comfortable.

Visa & travel guide →

Stay Informed About Advances in Cancer Care

Contact our team to learn more about the latest oncology developments and treatment options at Beijing Arion Cancer Hospital.

Book a Consultation Chat on WhatsApp